Healthcare/Biotech
A Clinically Translatable Multimodal Deep Learning Model for HRD Detection from Histopathology Images
The TRINITY AI model integrates imaging, transcriptomic, and clinico-molecular data to predict Homologous Recombination Deficiency (HRD) status from H&E-stained whole-slide images. This offers a rapid, cost-effective alternative to traditional NGS, improving patient stratification for PARP inhibitor and platinum-based therapies in breast and ovarian cancers.
Executive Impact: Enhanced Precision & Efficiency
TRINITY AI revolutionizes HRD detection, offering substantial improvements in diagnostic accuracy, cost-effectiveness, and turnaround time for oncology patients.
0.0
OV AUC-ROC
0
Per Patient Cost Reduction
0
Reduced Turnaround Time
Deep Analysis & Enterprise Applications
Select a topic to dive deeper, then explore the specific findings from the research, rebuilt as interactive, enterprise-focused modules.
Summary of TRINITY AI Model
HRD Detection Improvements
Future Directions
Summary of TRINITY AI Model
TRINITY is an AI-driven multi-omics model that integrates imaging, AI-inferred transcriptomic, and clinico-molecular data. It predicts Homologous Recombination Deficiency (HRD) status in breast and ovarian cancers, guiding PARP inhibitor and platinum-based therapies.
HRD Detection Improvements
TRINITY demonstrated superior performance with AUC-ROC values of 0.91 for TCGA-breast and 0.89 for an external cohort. It offers a rapid, cost-effective alternative to NGS, supporting broader patient access and precise treatment stratification.
Future Directions
Future work includes validation on larger, diverse pan-cancer datasets, integration with liquid biopsy, and prediction of treatment response beyond binary HRD status. Expansion to other cancer types like pancreatic and prostate cancer is also a key direction.
0.9121
AUC-ROC for TCGA-Breast Cancer
Enterprise Process Flow
WSI Processing
→
AI-Inferred Transcriptomics
→
Clinical Data Pipeline
→
Dedicated Encoders
→
Multi-Modal Contrastive Learning
→
HRD/HRP Status Prediction
TRINITY AI vs. Traditional NGS: A Comparison
| Feature | TRINITY AI | Traditional NGS |
|---|---|---|
| Cost | Low (Digital Scanning/Processing) | High ($3000-$5000) |
| Turnaround Time | Rapid (~24 hours) | Long (~21 days) |
| Modalities | Multimodal (Image, Transcriptome, Clinical) | Single (Genomic Sequencing) |
| Failure Rates | Low | High (Tissue-dependent) |
| Target Genes | Comprehensive (260 genes) | Limited (Misses some HRD genes) |
Accelerating Ovarian Cancer Diagnosis
A major healthcare provider needed faster, more accurate HRD detection for ovarian cancer patients to optimize PARP inhibitor therapy. Implementing TRINITY AI reduced diagnosis time by 20 days and improved patient stratification for targeted treatments, leading to better clinical outcomes and significant cost savings by reducing unnecessary NGS tests. The model's 0.91 AUC for ovarian cancer demonstrated its strong clinical utility.
Calculate Your Potential ROI
See how much time and cost your enterprise could save by integrating advanced AI for pathology analysis. Adjust the parameters below to get a tailored estimate.
Annual Cost Savings
$0
Hours Reclaimed Annually
0
Your AI Implementation Roadmap
A structured approach ensures seamless integration and rapid value realization for your enterprise.
Phase 1: Discovery & Strategy (2-4 Weeks)
Initial consultations, needs assessment, data readiness evaluation, and defining specific HRD detection goals and integration points within your existing pathology workflows.
Phase 2: Customization & Training (4-8 Weeks)
Tailoring TRINITY AI to your specific data, infrastructure, and clinical requirements. This includes fine-tuning models, establishing data pipelines for WSIs and clinico-molecular data, and initial validation.
Phase 3: Deployment & Integration (3-6 Weeks)
Seamless integration of TRINITY AI into your digital pathology system, LIMS, and EMR. Includes robust testing, user training for pathologists and lab staff, and establishing monitoring protocols.
Phase 4: Optimization & Scaling (Ongoing)
Continuous performance monitoring, iterative model improvements, and expansion to additional cancer types or biomarkers based on your evolving enterprise needs and clinical validation data.
Ready to Transform Your Oncology Diagnostics?
Leverage TRINITY AI to enhance HRD detection, reduce costs, and accelerate patient care. Book a complimentary consultation with our AI specialists.
Ready to Get Started?
Book Your Free Consultation.
Let's Discuss Your AI Strategy!
Lets Discuss Your Needs
Select a Date
Sun
Mon
Tue
Wed
Thu
Fri
Sat